Santarus,
Inc. SNTS today announced the completion of enrollment in
the CONTRIBUTE clinical study designed to evaluate the incremental
benefit of adding UCERIS (budesonide) extended release 9 mg
tablets to oral aminosalicylate (5-ASA) therapy for the induction of
clinical remission in adult patients with active, mild to moderate
ulcerative colitis. UCERIS is currently approved in the U.S. for the
induction of remission in patients with active, mild to moderate
ulcerative colitis.
A total of 509 patients were enrolled in the CONTRIBUTE study, a
multicenter, randomized, double-blind, placebo controlled clinical
trial. The primary endpoint of the study is clinical remission, defined
as a score of 0 for both rectal
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in